




Up-to-date Mapping of COVID-19 Treatment and Vaccine Development



CORONAVIRUS CASCADE

One estimate suggests that more than 200,000 coronavirus-related journal articles and preprints had been published by early December.



*Estimates differ depending on search terms, database coverage, and definitions of what counts as a scientific article; some preprints were posted on multiple sites online.

©nature

COVID-19 Research Publishing

- Around **4% of the world's research** output was devoted to the coronavirus in 2020
- December 2020: More than 200,000 coronavirus-related journal articles
- April 2021: More than 374,000 publications
- Information surplus
- Various topics
- Efficient processing is required

H. Else, "How a torrent of COVID science changed research publishing - in seven charts," Nature, vol. 588, no. 7839. NLM (Medline), p. 553, 01-Dec-2020.
<https://reports.dimensions.ai/covid-19/>



Up-to-date Mapping of COVID-19 Treatment and Vaccine Development


- The goal: to provide up-to-date information on the research of COVID-19 treatment options for researchers, medical providers, as well as the general public.
- Identification of relevant research articles related to COVID-19 treatment using renowned scientific databases, in particular PubMed, PMC, bioRxiv, and data from the COVID-19 Open Research Dataset Challenge.
- Provided in a freely accessible database at <https://covid19-help.org/>
- As of April 7, 2021, there are **1,513** substances in the database of **potential drugs and vaccines for COVID-19**.



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.




HOW IT WORKS



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.



Main Benefits of the Project



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.














Easy-to-use Database

Filter the drugs by their COVID-19 status , phase of research  and how they help 

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.

Advanced search

Show 10  entries

Substance 	COVID-19 status 	Phase of research 	How it helps 	Latest publication 	Supporting references 	Contradictory references 
Select substances 	Select COVID-19 status 	Select phase of research 	Select how they help 			
Tocilizumab	Recommended by China's NHC Guidelines	Used to treat other disease	Other treatment	Feb/06/2021	75	16
Remdesivir	Approved by FDA	Experimental	Antiviral	Feb/06/2021	55	4
Hydroxychloroquine sulfate	Potential treatment - clinical evidence	Used to treat other disease	Antiviral	Feb/18/2021	39	39
Methylprednisolone	Potential treatment - clinical evidence	Used to treat other disease	Other treatment	Feb/04/2021	31	4
Convalescent plasma	Emergency use authorization	Experimental	Antiviral	Feb/12/2021	31	5



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.



Easy-to-use Database

[HOME](#)[COVID-19 ▾](#)[DATABASE](#)[BLOG](#)[PROJECT AIM ▾](#)[Join the effort](#)

Substances

BNT162b2

References

No results

Blog

COVID-19 Vaccines Comparison: AstraZeneca, Moderna, and **Pfizer**/BioNTech

Frequently Asked Questions About COVID-19 Vaccines

Medical Innovations Boosted by the COVID-19 Pandemic

[Show all results](#)

Up-to-date mapping of
treatment and vaccine
development

Find out which substances could be effective
worldwide



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.

Remdesivir

Nucleoside triphosphate (NTP) analogue.



Phase of research
Approved by FDA



How it helps
Antiviral



Drug status
Experimental

55

Supporting references

4

Contradictory references

48

Clinical trials

Supporting references

Link ?	Tested on ?	Impact factor ?	Notes ?	Publication date ?	DB entry date ?
A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma small molecule mixed substance antibody case report RdRpol immunotherapy	An X-linked agammaglobulinemia patient.	6.78	Combined with convalescent plasma therapy. Observed clinical improvement in an X-linked agammaglobulinemia patient requiring ICU care, who did not respond to supportive care.	Feb/06/2021	Feb/19/2021

Contradictory references

Link ?	Tested on ?	Impact factor ?	Notes ?	Publication date ?	DB entry date ?
Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results preprint	Patients		little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay	Oct/15/2020	Oct/16/2020

Clinical trials ?

ID	Title	Status	Phase	Start date	Completion date
NCT04391309	COVID-19 and Anti-CD14 Treatment Trial	Not yet recruiting	Phase 2	Feb/01/2021	Jan/01/2022
NCT04647669	World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments	Not yet recruiting	Phase 3	Feb/01/2021	Dec/31/2021

Substance Subpage

- Key information on top
- Easy navigation
- List of references
 - Supporting references
 - Contradictory references
 - Clinical trials
- Additional information
 - General information
 - 2D structure image and SMILES formula
 - Synonyms
 - Other data





Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.



Substances in the Database

Since the launch of the website (April 2020), there has been a steady increase in the number of substances (COVID-19 treatment and vaccine candidates) in the database. As of April 7, 2021, there are **1,513** substances.



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.

Project Dissemination

- Directed communication with referenced authors
- **LinkedIn** and **Facebook** (business pages created to provide project updates)
- **Newsletter**
- Information about the project posted to various online channels: **ResearchGate**, **Reddit**, **Quora**, **EOSC Liaison Platform**, **Facebook** forums
- **Blogs** on the website



Medical Innovations Boosted by the COVID-19 Pandemic

Emma Wilson, PhD
05/09/2021


Every crisis has a silver lining. COVID-19 pandemic has brought a lot of pain and suffering, but it also helped to speed medical innovations that are going to stay with us.



The Johnson & Johnson COVID-19 Vaccine: A Gamechanger?

Emma Wilson, PhD
04/10/2021

Recently, a new COVID-19 vaccine produced by Johnson & Johnson has entered the market. What do we know about it, and how does it impact the vaccination plan?



The Threat of the South African Coronavirus Variant

Emma Wilson, PhD
02/10/2021

The epidemic from the beginning of vaccination against COVID-19 is disturbed by discovering several distinct virus variants that could escape the protection of the current vaccines. Here we discuss perhaps the most worrying variant of the time, first identified in South Africa.



Frequently Asked Questions About COVID-19 Vaccines

Emma Wilson, PhD
02/09/2021

Compared with the usual vaccine development process, we have witnessed an unprecedented effort resulting in multiple COVID-19 vaccines developed in under a year. It is only natural that people have many questions, but the sheer amount of information might be overwhelming. Here we answer some of the frequently asked questions on COVID-19 vaccines.



What Is Behind the Fear of the COVID-19 Vaccine?

Emma Wilson
04/09/2021

Vaccination is among the biggest achievements of medicine. But even though vaccines have saved millions of lives, people are still suspicious of them. Let's look at the reasons why some people are opposed to vaccines.



COVID-19 Vaccines Comparison: AstraZeneca, Moderna, and Pfizer/BioNTech

Emma Wilson, PhD
09/05/2021

At the beginning of 2021, many countries have approved more than one COVID-19 vaccine. What are the differences between the available options? Here we compare the three most-discussed COVID-19 vaccines.



On the Pfizer/BioNTech Vaccine

Emma Wilson, PhD
06/12/2020

Approval of several vaccines against COVID-19 developed in under a year elicits both caution and optimism. Do they work, and more importantly - are they safe? Let us look at the first vaccine approved in western countries - BNT162b2 developed by Pfizer/BioNTech.



Milk calling over SARS-CoV-2 - better safe than sorry?

Emma Wilson, PhD
12/01/2021

The mass culling of farmed ruminants due to the spread of the novel coronavirus came as a shock to most. Was it a necessary measure or a better-safe-than-sorry precaution? Should we be wary of not only other people but animals as well?



Testing People For COVID-19

Emma Wilson, PhD
11/12/2020

It is crucial to do what we can to stop the spread of COVID-19. With similar symptoms to other respiratory diseases and many asymptomatic people, we need reliable ways to detect the virus behind the pandemic. What are our options?




Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.




Traffic at <https://covid19-help.org/>

Since the launch of the website (April 2020), there has been a significant increase in the number of visitors – about 40,000 unique users on the website from all around the world



Data from Google Analytics



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.

Our Team

info@covid19-help.org



Michal Ivantyšin
Founder



Ivana Mišová
Biochemistry and
Genetics Researcher



Tomáš Wagner
Web developer



Katarína Rausová
Marketing Specialist



Ján Frankovský
Genetics Researcher



Zoltán Halász
Machine Learning
Specialist



Up-to-date mapping of COVID-19 treatment and vaccine development has received funding from the EOSC Secretariat project. EOSCsecretariat.eu has received funding from the European Union's Horizon Programme call H2020-INFRAEOSC-05-2018-2019, grant Agreement number 831644.